UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for chronic kidney disease (CKD) in the United Kingdom. Explore treatment pathways including SGLT2 inhibitors, dialysis alternatives, and transplant research.
CKD affects ~7.2 million people in the UK (over 10% of the population), though many are undiagnosed. It ranges from mild (stage 1-2) to kidney failure (stage 5, requiring dialysis or transplant). Common causes include diabetes, high blood pressure, and glomerulonephritis. Early detection through blood and urine tests allows treatment to slow or prevent progression.
Major advances in CKD treatment: SGLT2 inhibitors (dapagliflozin, empagliflozin) now recommended for CKD regardless of diabetes status - they slow kidney function decline by ~40%. Non-steroidal MRAs (finerenone) for diabetic kidney disease. For IgA nephropathy: targeted-release formulation of budesonide (Nefecon) and sparsentan. Blood pressure control and RAAS blockade remain foundational.
For end-stage kidney disease: haemodialysis (typically 3x/week at hospital or home), peritoneal dialysis (daily at home), or kidney transplantation (the best treatment for most patients). The NHS performs ~3,000 kidney transplants yearly. Living donor transplantation has excellent outcomes. Novel approaches: wearable artificial kidneys, bioengineered kidneys, and xenotransplantation (pig kidneys) in early trials.
Active UK CKD trials include: next-generation SGLT2/finerenone combinations, novel anti-fibrotic agents, gene therapy for polycystic kidney disease, stem cell therapies, xenotransplantation, improved dialysis membranes, home haemodialysis programmes, and precision medicine for glomerular diseases. Kidney Research UK is the major charity funder.
Free AI-powered matching - no signup required
Search CKD Trials →